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osting by EAbstract The aim of the present work was to study the effect of tobacco smoking on disease
progression in rheumatoid arthritis patients and its relation to anti-cyclical citrullinated peptide
(anti-CCP) antibodies. The study included 54 patients; 20 non-smokers, 9 ex-smokers, 14 mild to
moderate smokers and 11 heavy smokers. Fifteen normal volunteers were also studied as controls.
Disease stage was clinically and radiologically determined, rheumatoid factor (RF) and anti-CCP
antibodies were measured in serum. Higher percentage of severe disease (stage III) was seen in
heavy smoker patients than mild to moderate smokers (54.6% versus 35.7%) and in moderate
smokers than ex-smokers (35.7% versus 33.6%). Lowest percentage of severe disease was seen in
non-smokers (15%). RF and anti-CCP were signiﬁcantly higher in smoker than non-smoker and
in heavy than mild to moderate smoker patients (p< 0.01, p< 0.05 and p< 0.01, p< 0.001,
respectively). In smoker patients, both RF and anti-CCP antibodies correlated signiﬁcantly and
positively with smoking index (r= 0.581, p< 0.001; r= 0.661, p< 0.001). Also, smoking index
and anti-CCP correlated signiﬁcantly and positively with disease stage (r= 0.424, p< 0.05;
r= 0.523, p< 0.01). It appears from our results that, tobacco smoking mostly play a role inyahoo.com (M.M.Alsalahy).
ity. All rights reserved. Peer-
d University.
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76 M.M. Alsalahy et al.progression of rheumatoid arthritis through tissue protein citrullination. So all rheumatoid arthritis
patients must quit completely to achieve a good control.
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Tobacco smoking constitutes a major public health problem all
over the world because of its widespread consumption and difﬁ-
cult quitting (Renard et al., 2008).Many authors linked tobacco
consumption to auto-immune disorders mainly through tissue
protein citrullination whichmakes them escape normal immune
tolerance (Costenbader and Karlson, 2006). Tobacco smoking
was claimed by many research workers to be a risk factor for
occurrence and progression of rheumatoid arthritis (RA)
(Hutchison et al., 2001). We carried out this study to ﬁnd out
the relation (if any) between tissue protein citrullination, disease
progression and tobacco smoking in RA patients.
2. Subjects and methods
Complying with ethical guidelines of scientiﬁc research com-
mittee at Benha University Hospitals, we selected 54 rheuma-
toid arthritis patients from those attending rheumatology,
internal medicine and chest medicine outpatient clinics.
Patients were diagnosed according to the 1987 revised criteria
of American Rheumatism Association (Arnett et al., 1988).
Patients inclusion criteria: current smoker, ex-smoker and
non-smoker rheumatoid arthritis patients.
Exclusion criteria: patients with diabetes mellitus, chronic
renal or liver disease, thyroid disease, psoriasis or other
extensive dermatosis and those on high doses of anti-inﬂam-
matory or immune-suppressive therapy where excluded to
avoid the effect of these factors on blood levels of anti-
CCP antibodies and rheumatoid factor (RF) (Eisenbarth
and Homann, 2006).
All patients were males as no smoker females were met.
Twenty patients were non-smokers and considered as group
I, 9 ex-smoker patients (>5 years abstinence) considered as
group II, 14 mild to moderate current smokers (smoking
index < 15 pack/year) considered as group III and 11 heavy
current smokers (smoking index > 20 pack/year) considered
as group IV. Fifteen healthy, age matched male subjects
were also selected as controls: 8 non-smokers and consid-
ered as group V, while the remaining 7 are heavy smokers
and considered as group VI. The study was carried out be-
tween March (2008) and January (2009) and consent was
taken from all patients and control subjects enrolled in
the study.
Full history taking and clinical examination as well as gen-
eral lab studies including CBC, ESR, liver and kidney func-
tions and random blood sugar were done to all patients to
conﬁrm selection criteria. X-ray (as well as CT and/or MRI
if required) examination of the affected joints was also done.
Rheumatoid patients were classiﬁed according to their disease
stage depending on clinical and radiological ﬁndings: stage I –
mild, stage II – moderate, stage III – severe and stage IV – ter-
minal (Steinbroker et al., 1949).
RF was measured in blood of all subjects using IgG ELISA
kits from International Biological Laboratory (IBL, Germany)and patient serum samples (Swedler et al., 1997). The rheuma-
toid factor IgG ELISA is based on the principle of the enzyme
immunoassay (EIA) where goat-IgG is bound on the surface of
the microtiter strips. Diluted patient serum or ready to use
standards and controls are pipetted into the wells of the micro-
titer plate. A binding between the rheumatoid factor of the ser-
um and the immobilized IgG takes place. After a 1-h
incubation at room temperature, the plate is rinsed with di-
luted wash buffer in order to remove unbound material. Then
the anti-human IgG peroxidase conjugate is added and incu-
bated for 30 min. After a further washing step, the tetra-
methyl-benzidine (TMB) substrate solution is pipetted
inducing the development of a blue dye in the wells. The color
development is terminated by the addition of a stop solution,
which changes the color from blue to yellow. The resulting
dye is measured spectrophotometrically at the wavelength of
450 nm. The concentration of IgG rheumatoid factor is di-
rectly proportional to the intensity of the color. Levels less
than 20 U were considered negative, 20–39 U: equivocal or
weakly positive, 40–59 U: positive and 60 U or more were con-
sidered strongly positive.
Tissue protein citrullination is reﬂected in blood as antibod-
ies against cyclical citrullinated peptides (anti-CCP antibod-
ies). These antibodies were measured using also an ELISA
assay (DIASTAT anti-CCP kits, Axis-Shield Diagnostics
Ltd., Dundee, UK) (Niewold et al., 2007).
Sampling: serum or plasma (EDTA, lithium heparin, so-
dium citrate) samples; grossly haemolysed or turbid samples
were not used. Samples kept at 2–8 C if tested within 3 weeks
and at 20 C if kept for longer time.
Preparation for the assay: allow all kit components,
including the microtitre strips, to warm up to 18–25 C for
30–60 min before use. Mix reagents by gentle inversion.
The reference control is not diluted but the following solu-
tions were diluted as follows: wash buffer concentrate 1 vial
in 375 mL distilled/deionised water, sample diluent concen-
trate 1 vial in 100 mL distilled/deionised water and positive
and negative controls/samples: 10 lL in 1 mL diluted sample
diluent.
Steps: pipette 100 lL reference control/calibrators in dupli-
cate, pre-diluted (1:100) positive and negative controls, and
pre-diluted (1:100) patient samples into appropriate wells. This
step should not exceed 15 min for any one set of calibrators/
controls/samples. Incubate 60 ± 10 min at 18–25 C. Decant
strip contents by quick inversion over a sink suitable for the
disposal of biological materials, bearing in mind the potential
infective hazard of the samples. Blot inverted strips well with
paper towels. Wash wells three times with a minimum of
200 lL diluted wash buffer. Decant and blot after each wash
step. Add 100 lL conjugate to each well. Incubate
30 ± 5 min at 18–25 C. Repeat steps 4 and 5. Add 100 lL
substrate to each well. Incubate 30 ± 5 min at 18–25 C. Do
not decant. Add 100 lL stop solution to each well, in the same
order and rate as the substrate. Tap wells gently to mix. Strips
then read spectrophotometrically within 24 h at 550 nm (540–
565 nm).
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Collected data were analyzed using the software KyPlot.2001,
version 2-b (Kioshi, Japan) for windows. Data were presented
as mean (M) ± standard error of mean (SE). Comparisons
were done by parametric, two tailed t-test for unpaired values,
while correlations were done by linear correlation and regres-
sion analysis.
4. Results
Clinical characteristics of all subjects included in the study are
shown in Table 1. Forty-ﬁve percent of non-smoker patients
were in disease stage I, 40% were in stage II and only 15%
were in stage III. For ex-smokers, 22% were in stage I,
44.4% in stage II and 33.6% in stage III. In mild to moderate
smoker patients, 21.4% were in stage I, 42.9% in stage II and
35.7% in stage III. More severe disease was seen in heavy smo-
ker group as only 9% of them were in stage I, 36.4% in stage II
and 54.6% in stage III. Chi square test for independence
showed a positive relation between disease stage and degree
of smoking (Chi square: 51.699, degree of freedom: 4, alpha
probability: <0.01) (Table 2).
RF was negative in smoker and non-smoker controls
(14.125 ± 1.092 and 15.414 ± 1.147 U/L [M± SE], respec-
tively) and was positive and signiﬁcantly higher in smoker than
non-smoker patients (p< 0.01 and p< 0.001 for moderate
and heavy smokers, respectively). Also heavy smoker patients
have signiﬁcantly higher RF titer than mild to moderate smok-
ers (p< 0.05). Ex-smoker patients also showed signiﬁcantly
higher titer than heavy smoker controls (p< 0.001) but
showed a non-signiﬁcant difference from non-smoker patients
(p> 0.05) (Table 3).
Comparison of anti-CCP antibodies between different
groups showed that, although blood levels in normal controlsTable 2 Disease stage according to smoking index in studied patie
Stage Group
I (non-smokers)
(%)
II (ex-smokers)
(%)
III (moderate smokers)
(%)
IV (h
(%)
I 45 22 21.4 9
II 40 44.4 42.9 36.4
III 15 33.6 35.7 54.6
** Signiﬁcant.
Table 1 Clinical characteristics of patients and control subjects inc
Group I Group II
Description NS patients ES patients
Number 20 9
Age in years (M± SD) 37.1 ± 6.172 41.78 ± 5.262
Stage I (%) 45 22
II (%) 40 44.4
III (%) 15 33.6
ESR: mm/h (M± SD) 43.43 ± 5.122 45.55 ± 6.453
RF: U/L (M± SD) 43.95 ± 6.557 42.78 ± 6.057
NS, non-smoker; ES, ex-smoker; MS, mild to moderate smokers; HS, hewere very low, yet they were higher in heavy smokers
(7.571 ± 0.996 versus 4.562 ± 0.290 U/mL [M± SE]) and
the difference between them was signiﬁcant (p< 0.01). Blood
levels in heavy smoker patients were much higher than heavy
smoker controls and the difference between both was signiﬁ-
cant (p< 0.001). Also, a signiﬁcant difference was seen be-
tween mild to moderate smoker and non-smoker patients
(p< 0.01). In patients, heavy smokers showed much higher
levels of anti-CCP antibodies than mild to moderate smokers
(47 ± 2.268 versus 35.5 ± 1.666 U/mL [M± SE]) and the dif-
ference was signiﬁcant (p< 0.001). A signiﬁcant difference
was also seen between ex-smoker patients and heavy smoker
controls (p< 0.001). No signiﬁcant difference was seen be-
tween ex-smoker and non-smoker patients (p> 0.05) (Table
3).
RF and anti-CCP antibodies showed signiﬁcant positive
correlation to SI (r= 0.592, p< 0.001and r= 0.661,
p< 0.001, respectively). SI and anti-CCP antibodies also
showed a signiﬁcant direct relation to disease stage
(r= 0.424, p< 0.05 and r= 0.523, p< 0.01, respectively)
(Table 4). Hand X-rays of three patients with different stages
of RA are shown in Fig. 1.
5. Discussion
Tobacco smoking is one of the environmental factors that
predispose to rheumatoid arthritis and is linked epidemiolog-
ically to more severe forms of the disease (Hutchison et al.,
2001; Majka and Holers, 2006). Citrullination of tissue pro-
teins caused by tobacco smoking was considered by some to
be the main mechanism by which smoking induces and
worsens auto-immune diseases (Costenbader and Karlson,
2006). We carried out this study to discover any possible ef-
fect of tobacco smoking on disease progression in rheuma-
toid arthritis patients as well as its relation to tissuents and Chi square test.
eavy smokers) Chi square Degree of freedom Alpha probability
51.699 4 <0.001**
luded.
Group III Group IV Group V Group VI
MS patients HS patients NS controls HS controls
14 11 8 7
40.71 ± 5.135 42 ± 4.857 38.13 ± 3.603 37.57 ± 6.55
21.4 9 – –
42.9 36.4
35.7 54.6
49.44 ± 9.122 53.71 ± 7.982 10.53 ± 0.651 13.11 ± 1.234
54.57 ± 12.92 68.72 ± 12.53 10.12 ± 3.09 15.71 ± 3.147
avy smokers.
Table 3 Comparison of rheumatoid factor (U/L) and anti-CCP antibodies (U/mL) between different groups included in the study.
Group I Group II Group III Group IV Group V Group VI
RF (M± SE) 43.95 ± 1.446 42.777 ± 2.019 54.571 ± 3.454 68.72 ± 3.778 14.125 ± 1.092 15.414 ± 1.189
Anti-CCP (M± SE) 27.55 ± 1.531 29.444 ± 3.082 35.5 ± 1.666 47 ± 2.268 4.562 ± 0.290 7.571 ± 0.996
Comparison RF Anti-CCP
Groups V and VI p> 0.05* p< 0.01**
Groups IV and VI p< 0.001** p< 0.001**
Groups I and III p< 0.01** p< 0.01**
Groups III and IV p< 0.05** p< 0.001**
Groups I and II p> 0.05* p> 0.05*
Groups II and VI p< 0.001** p< 0.001**
* Non-signiﬁcant.
** Signiﬁcant.
Table 4 Correlation between smoking index and each of RF, anti-CCP antibodies and disease stage in smoker patients.
M± SE Correlation Correlation coeﬃcient (r) p-value
SI 14.6 ± 2.917 SI with RF 0.581 <0.001**
RF 60.8 ± 4.114 SI with anti-CCP 0.661 <0.001**
Anti-CCP 29.36 ± 5.154 SI with disease stage 0.424 <0.05**
Disease stage 2.28 ± 0.211 Anti-CCP with disease stage 0.523 <0.01**
SI, smoking index; RF, rheumatoid factor.
** Signiﬁcant.
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In this study, higher percentage of advanced disease was
found in heavy smoker patients than all other groups and in
ex-smokers and mild to moderate smokers than non-smok-
ers. A signiﬁcant direct relation was also found between
severity of smoking (SI) and disease stage in smoker pa-
tients. This means that tobacco smoking could worsen dis-
ease condition in these patients. This agrees with Saag
et al. (1997), Fredreck (2000), and Mikuls et al. (2008). Saag
et al. assessed the severity of rheumatoid disease by radio-
logical evidence of bone destruction and found that patients
who smoked more than 25 pack/year had the severest form
of the disease and found also that subcutaneous nodules
were a common feature in them. They concluded that tobac-
co smoking adversely inﬂuence the severity of RA in a
potentially dose dependent fashion. Fredreck found a direct
relation between the overall severity of rheumatoid arthritis
and degree of smoking as well as RF seropositivity although
he could not ﬁnd a relation to the current disease activity.
Mikuls and coworkers studied disease severity and seropos-
itivity in 300 of African Americans with recent onset RA
and found more severe forms with more skin nodules in cur-
rent smokers than non-smokers and ex-smokers and in
heavy than moderate smokers.
Surprisingly and in disagreement with our results, Finckh
et al. (2007) studied 554 RA patients over a 3 years period
and said that disease progression and joint damage has the
same rate in both smokers and non-smokers. Moreover they
claimed that heavy smokers have a lesser tendency for disease
progression and concluded that tobacco smoking does not ap-
pear to accelerate joint damage in rheumatoid patients. AlsoWesthoff et al. (2008) showed that, although tobacco smoking
decreased the efﬁcacy of anti RA drugs and caused higher
seropositivity for RF, yet it does not affect radiological pro-
gression of the disease.
In our study, RF titer was signiﬁcantly higher in heavy
smoker patients than mild to moderate smokers and in these
patients than in patients who never smoked. Also, a signiﬁcant
direct relation was seen between RF and smoking severity (SI).
This result is supported by the work of many authors. Stolt
et al. (2003) studied 679 patients within 4 year period (1996–
2000) in a deﬁned area of Sweden and found high risk for
sero-positive RA among current smokers and ex-smokers than
non-smokers. Although Finckh et al. (2007) found no signiﬁ-
cant difference between smokers and non-smokers in disease
progression, yet they found higher levels of RF in smoker pa-
tients. Also, Saag et al. (1997) showed a signiﬁcant association
between SI and titer of RF. As stated before, Mikuls et al.
(2008) during their work on African American patients found
high seropositivity for RF among heavy smoker patients. On
the other hand, Lee et al. (2009) randomly studied RF in sera
of 241 RA patients from a large rheumatology clinic aiming at
evaluation of their role in the clinical situation of rheumatoid
disease. They found a non-signiﬁcant difference in RF titer be-
tween smokers and non-smokers, although the difference for
anti-CCP antibodies was signiﬁcant.
As regards anti-CCP antibodies, our present work showed
signiﬁcantly higher levels of these antibodies in heavy smokers
than mild to moderate smokers and in the later patients than
non-smokers. Also, a highly signiﬁcant direct relation was
found between these antibodies and SI. This means that tobac-
co smoking proportionally increases these antibodies in RA
patients who smoke. In other words, it increases tissue protein
a 
b  
c 
Figure 1 X-ray of hands of three of RA patients included in our
study. (a) Stage I disease: soft tissue swelling in proximal inter-
phalangeal joint. (b) Stage II disease: juxta-articular osteoporosis
with erosions in the left ﬁrst proximal interphalangeal joint. (c)
Marked juxta-articular osteoporosis in both hands with marginal
erosions in proximal interphalangeal joints and ulnar deviation.
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with many published research works. In the African American
group of patients studied by Mikuls et al. (2008) signiﬁcantly
higher levels of anti-CCP antibodies were found in heavy
smokers than moderate smokers and in mild to moderate
smokers than non-smokers. Lee et al. (2009) found a highly
signiﬁcant difference in these antibodies between smoker and
non-smoker RA patients, although RF was not signiﬁcantly
different between them as stated before. Michou et al. (2008)
studied the relation between human leukocyte antigen (HLA)
and anti-CCP antibodies in a French population with RA
and found signiﬁcantly higher levels of these antibodies in
smokers with a direct relation to the cumulative dose of
smoking.
In this study, we found a positive Chi square test as well as
a signiﬁcant direct relation between anti-CCP antibody levels
and disease stage which implies a possible role of these anti-
bodies in the pathology of rheumatoid disease. More over it
is also possible that smoking increases the risk of RA and
worsens the ongoing disease through these antibodies. Thisagrees with Navarro et al. (2006), van Oosterhout et al.
(2008), and Turesson et al. (2005). All of these authors showed
a more severe form of the disease besides a higher incidence of
extra articular joint affection in association with higher levels
of these antibodies.
Although not exactly known how does tobacco smoking in-
creases the risk of RA and worsens its course, yet tissue protein
citrullination is considered by some authors to be the main
pathogenetic mechanism (van Gaalen et al., 2005). Kobayashi
et al. (2008) proposed another mechanism by which this haz-
ardous effect of smoke happens. These authors showed that to-
bacco smoking induces an inﬂammatory cytokine response
especially of IL-1b and TNFa. This inﬂammatory response is
mediated by hydrocarbons (the main constituent of tobacco
smoke, especially 2,3,7,8-tetrachlorodibenzo-p-dioxin) and is
most marked in the synovial ﬂuid.
Genetic factors, especially genes encoding for HLA-DRB1
and protein tyrosine phosphatase, non-receptor type 22
(PTPN22) antigens, were also claimed to predispose smokers
for RA and RA patients for more severe forms of the disease
(Michou et al., 2008).
Finally, RA appears to results from an interaction between
genetics, the immune system and the environment.
6. Conclusion
From our results we can conclude that, tobacco smoking
mostly play a role in progression of rheumatoid arthritis, most
likely, through tissue protein citrullination. So, for achieving
optimal control of rheumatoid arthritis, all smoker patients
must quit.
References
Arnett, F.C., Edworthy, S.M., Bloch, D.A., Mcshane, D.J., Fries, J.F.,
Cooper, N.S., Healey, L.A., Kaplan, S.R., Liang, M.H., Luthra,
H.S., Medsger, T.A., Mitchell, D.M., Neustadt, D.H., Pinals, R.S.,
Schaller, J.C., Sharp, J.T., Wilder, R.L., Hunder, G.G., 1988. The
American Rheumatism Association 1987 revised criteria for the
classiﬁcation of rheumatoid arthritis. Arthritis Rheum 31, 315–324.
Costenbader, K.H., Karlson, E.W., 2006. Cigarette smoking and
autoimmune disease: what can we learn from epidemiology? Lupus
15 (11), 737–745.
Eisenbarth, S.C., Homann, D., 2006. Type 1 Diabetes: Cellular,
Molecular and Clinical Immunology. Primer: Immunology and
Autoimmunity. An Online CME Topic 8/2008 (Chapter 1).
<http://uchsc.edu/misc/diabetes/books/type1/type1_ch1.html>.
Finckh, A., Dehler, S., Costenbader, K.H., Gabay, C., 2007. Cigarette
smoking and radiographic progression in rheumatoid arthritis.
Annals of the Rheumatic Diseases 66, 1066–1071.
Fredreck, W., 2000. The effect of smoking on clinical, laboratory, and
radiographic status in rheumatoid arthritis. Journal of Rheuma-
tology 27, 630–637.
Hutchison, D., Shepstone, L., Moots, R., Lear, J.T., Lynch, M.P.,
2001. Heavy cigarette smoking is strongly associated with rheu-
matoid arthritis (RA), particularly in patients without a family
history of RA. Annals of Rheumatic Diseases 60, 223–227.
Kobayashi, S., Okamoto, H., Iwamoto, T., Toyama, Y., Tomatsul, T.,
Yamanaka, H., Momohara, S., 2008. A role for the aryl hydro-
carbon receptor and the dioxin TCDD in rheumatoid arthritis.
Rheumatology 47, 1317–1322.
Lee, D.M., Phillips, R., Hagan, E.M., Chibnik, L.B., Costenbader,
K.H., Schur, P.H., 2009. Quantifying anti-cyclic citrullinated
peptide titres: clinical utility and association with tobacco exposure
80 M.M. Alsalahy et al.in patients with rheumatoid arthritis. Annals of the Rheumatic
Diseases 68, 201–208.
Majka, D.S., Holers, V.M., 2006. Cigarette smoking and the risk of
systemic lupus erythematosus and rheumatoid arthritis. Annals of
the Rheumatic Diseases 65, 561–563.
Michou, L., Teixeira, V.H., Pierlot, C., Lasbleiz, S., Bardin, T.,
Dieude´, P., Prum, B., Corne´lis, F., Petit-Teixeira, E., 2008.
Associations between genetic factors, tobacco smoking and auto-
antibodies in familial and sporadic rheumatoid arthritis. Annals of
the Rheumatic Diseases 67, 466–470.
Mikuls, T.R., Hughes, L.B., Westfall, A.O., Holers, V.M., Parrish, L.,
van der Heijde, D., van Everdingen, M., Alarco´n, G.S., Conn,
D.L., Jonas, B., Callahan, L.F., Smith, E.A., Gilkeson, G.,
Howard, G., Moreland, L.W., Bridges, S.L., 2008. Cigarette
smoking, disease severity and autoantibody expression in African
Americans with recent-onset rheumatoid arthritis. Annals of the
Rheumatic Diseases 67, 1529–1534.
Navarro, C., Ban˜ales, J.L., Nava, A., Mejia, M., Carrillo, G., Torres,
M., Reyes, P., Selman, M., 2006. Sera anti-cyclic citrulinated
peptide antibodies differentiate interstitial lung disease related to
rheumatoid arthritis from other lung diseases. Annals of the
Rheumatic Diseases 65 (Suppl. 2), 313.
Niewold, T.B., Harrison, M.J., Pajet, S.A., 2007. Anti-CCP antibody
as a diagnostic and prognostic tool in rheumatoid arthritis. The
Quarterly Journal of Medicine 100, 193–201.
Renard, S.I., Hepp, L.M., Daughton, D.M., 2008. Cigarette smoking
and disease. In: Fishman, A.P., Elias, J.A., Fishman, J.A., Grippi,
M.A., Senior, R.M., Pack, A.I. (Eds.), Fishman’s Pulmonary
Diseases and Disorders, fourth ed. McGraw-Hill, Inc., pp. 747–760
(Chapter 43).Saag, K.G., Cerhan, J.R., Kolluri, S., Ohashi, K., Hunninghake,
G.W., Schwartz, D.A., 1997. Cigarette smoking and rheumatoid
arthritis severity. Annals of the Rheumatic Diseases 56, 463–469.
Steinbroker, O., Trager, C.H., Batterman, R.C., 1949. Therapeutic
criteria in rheumatoid arthritis. JAMA 140, 659–662.
Stolt, P., Bengtsson, C., Nordmark, B., Lindblad, S., Lundberg, I.,
Klareskog, L., Alfredsson, L., 2003. Quantiﬁcation of the inﬂuence
of cigarette smoking on rheumatoid arthritis: results from a
population based case-control study, using incident cases. Annals
of the Rheumatic Diseases 62, 835–841.
Swedler, W., Wallman, J., Froelich, C.J., Teodorescu, M., 1997.
Routine measurement of IgM, IgG, and IgA rheumatoid factors:
high sensitivity, speciﬁcity, and predictive value for rheumatoid
arthritis. Journal of Rheumatology 24, 1037–1044.
Turesson, C., Jacobsson, L.T.H., Sturfelt, G., Matteson, E.L.,
Ro¨nnelid, J., 2005. Antibodies to cyclic citrulinated peptides are
associated with severe extra-articular manifestations in rheumatoid
arthritis. Annals of the Rheumatic Diseases 64 (Suppl. 3), 618.
van Gaalen, F., Ioan-Facsinay, A., Huizinga, T.W., Toes, R.M., 2005.
The devil in the details: the emerging role of anticitrulline
autoimmunity in rheumatoid arthritis. The Journal of Immunology
175, 5575–5580.
van Oosterhout, M., Bajema, I.M., Levarht, N.W.N., Toes, R.E.M.,
Huizinga, T.W.J., van Laar, J.M., 2008. Synovial differences
between anti-CCP positive and anti-CCP negative rheumatoid
arthritis. Annals of the Rheumatic Diseases 66 (Suppl. 2), 82.
Westhoff, G., Rau, R., Zinkl, A., 2008. Rheumatoid arthritis patients
who smoke have a higher need for DMARDs and feel worse, but
they do not have more joint damage than non-smokers of the same
serological group. Rheumatology 47, 849–854.
